110 related articles for article (PubMed ID: 38865122)
1. Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus.
Yen FS; Wang SI; Hsu CC; Hwu CM; Wei JC
JAMA Netw Open; 2024 Jun; 7(6):e2416578. PubMed ID: 38865122
[TBL] [Abstract][Full Text] [Related]
2. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.
Yen FS; Wei JC; Yu TS; Hung YT; Hsu CC; Hwu CM
JAMA Netw Open; 2023 Dec; 6(12):e2348431. PubMed ID: 38117497
[TBL] [Abstract][Full Text] [Related]
3. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
4. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
Yen FS; Hwu CM; Liu JS; Wu YL; Chong K; Hsu CC
Ann Intern Med; 2024 Jun; 177(6):693-700. PubMed ID: 38684099
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
[TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK
JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
[TBL] [Abstract][Full Text] [Related]
11. Dialysis Outcomes for Children With Lupus Nephritis Compared to Children With Other Forms of Nephritis: A Retrospective Cohort Study.
Wasik H; Chadha V; Galbiati S; Warady B; Atkinson M
Am J Kidney Dis; 2022 May; 79(5):626-634. PubMed ID: 34461164
[TBL] [Abstract][Full Text] [Related]
12. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
[TBL] [Abstract][Full Text] [Related]
13. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
Zhou J; Lee S; Leung KSK; Wai AKC; Liu T; Liu Y; Chang D; Wong WT; Wong ICK; Cheung BMY; Zhang Q; Tse G
ESC Heart Fail; 2022 Apr; 9(2):1388-1399. PubMed ID: 35132823
[TBL] [Abstract][Full Text] [Related]
14. Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study.
Park S; Jeong HE; Lee H; You SC; Shin JY
Cardiovasc Diabetol; 2023 Jul; 22(1):191. PubMed ID: 37507739
[TBL] [Abstract][Full Text] [Related]
15. Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Dave CV; Kim SC; Goldfine AB; Glynn RJ; Tong A; Patorno E
Circulation; 2021 Feb; 143(8):770-779. PubMed ID: 33302723
[TBL] [Abstract][Full Text] [Related]
16. Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes.
Huang YM; Chen WM; Jao AT; Chen M; Shia BC; Wu SY
Diabetes Metab; 2024 Jan; 50(1):101500. PubMed ID: 38036054
[TBL] [Abstract][Full Text] [Related]
17. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
Liu T; Fan Z; Xiao B; He C; Wang S
Cardiovasc Diabetol; 2024 Mar; 23(1):106. PubMed ID: 38528542
[TBL] [Abstract][Full Text] [Related]
18. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
[TBL] [Abstract][Full Text] [Related]
19. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
Mui JV; Li L; Chou OHI; Azfar N; Lee A; Hui J; Lee S; Tse G; Zhou J
Acta Diabetol; 2023 Jul; 60(7):917-927. PubMed ID: 37000300
[TBL] [Abstract][Full Text] [Related]
20. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes.
Wei J; Choi HK; Dalbeth N; Li X; Li C; Zeng C; Lei G; Zhang Y
JAMA Netw Open; 2023 Aug; 6(8):e2330885. PubMed ID: 37624597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
